NOVARTIS GENE THERAPIES joins the Rare Disease Action Forum

15 Mar, 2021

We are proud to welcome Novartis Gene Therapies as the newest member of the Rare Disease Action Forum. Reinforcing RDAF’s multi-stakeholder approach, they will be joining our other members from industry, patient organizations, healthcare professionals, and research organizations. We look forward to their contribution to the collaborative efforts at the RDAF multi-stakeholder platform. Together we will continue our efforts to improve access to diagnosis, treatment and care for patients with rare diseases in Switzerland.

Outcome of the RDAF 2023 General Assembly meeting

The Rare Disease Action Forum (RDAF) held its annual General Assembly meeting on 28 March 2023. During the meeting, the RDAF Secretariat presented an overview of the Association’s activities in 2022 and an outlook for 2023. The RDAF President underlined the progress...

13th International Rare Disease Day in Switzerland

The Rare Disease Action Forum supports the International Rare Disease Day, a globally coordinated movement that advocates for equal access to healthcare, treatments and diagnoses for patients with rare diseases, which takes place on 28 February. Watch the Rare Disease...